3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
55
Recurrence
7
Lymphoma
6
Neoplasms, Plasma Cell
5
Immunoglobulin Light-chain Amyloidosis
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Paraproteinemias
2
Neoplasms
2
Lymphoma, T-Cell
2
Lymphoma, Mantle-Cell
2
Leukemia, Myeloid, Acute
2
beta-Thalassemia
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thalassemia
1
Sarcoma, Myeloid
1
Prostatic Neoplasms
1
Plasmablastic Lymphoma
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Multi-centric Castleman's Disease
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphadenopathy
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
belantamab mafodotin
2
Dexamethasone
1
Cyclophosphamide
1
Bortezomib
1
Antineoplastic Protocols
1
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Amyloidosis
×
Bortezomib
×
90 days
×
Clear all
NCT07224672
2026-03-17
ALANIS
GlaxoSmithKline
Phase 2
Not yet recruiting
60 enrolled